Polaryx Therapeutics, Inc. (PLYX)
Nasdaq: PLYX · Pharmaceutical Preparations · Paramus, NJ · filing with the SEC since 2025
Who runs Polaryx Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Yang Alex Keun Mo
Chief Executive Officer. First filing Jan 2026, latest May 28, 2026, 0 filings in all.
Officers reporting now
4
of 8 people with a filing in the last fifteen months
Directors reporting now
4
8 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Yang Alex Keun Mo | Chief Executive Officer | Jan 2026 | May 28, 2026 | none |
| Landis G. Michael | Chief Financial Officer | Jan 2026 | Feb 20, 2026 | none |
| Bollinger Lisa | Chief Medical Officer | Jan 2026 | Jan 29, 2026 | none |
| O Andrew John | Chief Investment Officer | Jan 2026 | Jan 29, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Mstone Partners Healthcare Ltd | director | Jan 2026 | May 28, 2026 | none |
| Berger Mitchel | director | Jan 2026 | Jan 29, 2026 | none |
| Braun III Francis A | director | Jan 2026 | Jan 29, 2026 | none |
| Ryan Charles S. | director | Jan 2026 | Jan 29, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.